Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis' resubmission of the atrial fibrillation medication Multaq is expected to include data from the ongoing ATHENA trial.

You may also be interested in...



FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review

FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.

FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review

FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.

Sanofi-Aventis Gets Priority Review For Second-Generation Atrial Fib Drug

Approval could come in early 2009 for Cordarone successor Multaq.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel